Advertisement

Journal of Cancer Research and Clinical Oncology

, Volume 144, Issue 8, pp 1561–1568 | Cite as

Patterns of platinum drug use in an acute care setting: a retrospective study

  • Evangeline Armstrong-Gordon
  • Danijela Gnjidic
  • Andrew J. McLachlan
  • Bayan Hosseini
  • Andrew Grant
  • Philip J. Beale
  • Nial J. Wheate
Original Article – Clinical Oncology

Abstract

Purpose

Platinum drugs have been in use in cancer treatment for more than 40 years, but little is known about the pattern of their use. The aim of this study was to examine the patterns of platinum drug use, with a secondary aim to describe the occurrence of dose reductions.

Methods

A retrospective analysis was conducted of oncology pharmacy dispensing records from a single hospital in Australia. Data related to drug choice, regimen and dose reductions were included in this study if the patient had received their last round of chemotherapy between November 2014 and July 2015.

Results

Of the 156 patients included in the study, 46% were dispensed a platinum drug during their treatment. The most commonly dispensed drugs were cisplatin (40%), carboplatin (40%) and oxaliplatin (15%), while some patients (5%) received more than one platinum drug. Dose reductions were more common in patients who were treated with a platinum drug (73%) compared with patients treated with non-platinum drugs (55%). The most common reason for a dose reduction was cytopenia.

Conclusions

The findings suggest that platinum drugs remain one of the most commonly dispensed drugs to treat cancer patients and most patients receive a dose reduction during treatment.

Keywords

Platinum drugs Cancer Chemotherapy Prescribing Dose reductions 

Abbreviations

AUD

Australian dollar

BMI

Body-mass index

CRGH

Concord Repatriation General Hospital

EGFR

Epidermal growth factor receptor

IQR

Interquartile range

NSCLC

Non-small cell lung cancer

Notes

Acknowledgements

The authors wish to thank Rosemary Burke, Director of Pharmacy, CRGH, Robert Bayley, Oncology Pharmacy Department Manager, CRGH, and the rest of the Oncology Pharmacy Department at CRGH for graciously accommodating the researcher during the data collection phase and Professor Ines Krass, University of Sydney, Faculty of Pharmacy, for her assistance with statistical analysis.

Compliance with ethical standards

Conflict of interest

Author A declares that he/she has no conflict of interest. Author B declares that he/she has no conflict of interest. Author C declares that he/she has no conflict of interest. Author D declares that he/she has no conflict of interest. Author E declares that he/she has no conflict of interest. Author F declares that he/she has no conflict of interest. Author G declares that he/she has no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Sydney Local Health District Concord Hospital Human Research Ethics Committee (HREC Reference Number: LNR/17/CRGH/196).

References

  1. Apps MG, Choi EHY, Wheate NJ (2015) The state-of-play and future of platinum drugs. Endocr-Relat Cancer 22(4):219–233Google Scholar
  2. Australian Institute of Health and Welfare (2017) Cancer in Australia 2017. Cancer series. Australian Institute of Health and Welfare, CanberraGoogle Scholar
  3. Bagheri-Sereshki N, Hales BF, Robaire B (2016) The effects of chemotherapeutic agents, bleomycin, etoposide, and cisplatin, on chromatin remodeling in male rat germ cells. Biol Reprod 94(4):1–9CrossRefGoogle Scholar
  4. Bosl GJ, Bajorin DF, Sheinfeld J, Motzer RJ, Chaganti RS (2001) Cancer of the testis. Cancer principles practice of oncology, 6th edn. Lippincott Williams and Wilkins, Philadelphia, 1491–1518Google Scholar
  5. Cancer Institute NSW (2011) eviQ cancer treatments onlineGoogle Scholar
  6. Dyson PJ, Sava G (2006) Metal-based antitumour drugs in the post genomic era. Dalton Trans.  https://doi.org/10.1039/B601840H Google Scholar
  7. Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J (1984) Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res 44(11):5432–5438PubMedGoogle Scholar
  8. Einhorn LH, Foster RS (2006) Bleomycin, etoposide, and cisplatin for three cycles compared with etoposide and cisplatin for four cycles in good-risk germ cell tumors: is there a preferred regimen? J Clin Oncol 24(16):2597–2598CrossRefPubMedGoogle Scholar
  9. Giaccone G (2000) Clinical perspectives on platinum resistance. Drugs 59(4):9–17CrossRefPubMedGoogle Scholar
  10. Gibson D (2016) Platinum(IV) anticancer prodrugs—hypotheses and facts. Dalton Trans 45(33):12983–12991CrossRefPubMedGoogle Scholar
  11. Greystoke A, Steele N, Arkenau H-T, Blackhall F, Haris NM, Lindsay CR, Raffaele C, Voskoboynik M, Summers Y, So K, Ghiorghiu D, Dymond AW, Hossack S, Plummer R, Dean E (2017) SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. Br J Cancer 117:938–946CrossRefPubMedPubMedCentralGoogle Scholar
  12. Gutierrez F, Gonzalez-de-la-Fuente GA, Nazco GJ, Oramas J, Batista N (2016) Hematological toxicity of carboplatin for gynecological cancer according to body mass index. Eur J Clin Pharmacol 72(9):1083–1089CrossRefPubMedGoogle Scholar
  13. Hannon MJ (2007) Metal-based anticancer drugs: from a past anchored in platinum post-genomic future and biology. Pure Appl Chem 79(12):2243–2261CrossRefGoogle Scholar
  14. Harper BW, Krause-Heuer AM, Grant MP, Manohar M, Garbutcheon-Singh KB, Aldrich-Wright JR (2010) Advances in platinum chemotherapeutics. Chem Eur J 16(24):7064–7077CrossRefPubMedGoogle Scholar
  15. Husain K, Jagannathan R, Hasan Z, Trammell GL, Rybak LP, Hazelrigg SR, Somani SM (2002) Dose response of carboplatin-induced nephrotoxicity in rats. Pharmacol Toxicol 91(2):83–89CrossRefGoogle Scholar
  16. Johnstone TC, Park GY, Lippard SJ (2014) Understanding and Improving platinum anticancer drugs—phenanthriplatin. Anticancer Res 34(1B):471–476PubMedPubMedCentralGoogle Scholar
  17. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7(8):573–584CrossRefPubMedGoogle Scholar
  18. Kopp H-G, Kuczyk M, Classen J, Stenzl A, Kanz L, Mayer F, Bamberg M, Hartmann JT (2006) Advances in the treatment of testicular cancer. Drugs 66(5):641–659CrossRefPubMedGoogle Scholar
  19. Langer CJ, Moughan J, Movsas B, Komaki R, Ettinger D, Owen J, Wilson JF (2005) Patterns of care survey (PCS) in lung cancer: how well does current US practice with chemotherapy in the non-metastatic setting follow the literature? Lung Cancer 48(1):93–102CrossRefPubMedGoogle Scholar
  20. McEvoy LM, O’Toole SA, Spillane CD, Martin CM, Gallagher MF, Stordal B, Blackshields G, Sheils O, O’Leary JJ (2015) Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer. BMC Cancer 15:1–13CrossRefGoogle Scholar
  21. Muggia FM, Bonetti A, Hoeschele JD, Rozencweig M, Howell SB (2015) Platinum antitumor complexes: 50 years since barnett rosenberg’s discovery. J Clin Oncol 33(35):4219–4226CrossRefPubMedGoogle Scholar
  22. Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33(1):9–23CrossRefPubMedGoogle Scholar
  23. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T (1996) Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute’s anticancer drug screen panel. Biochem Pharmacol 52(12):1855–1865CrossRefPubMedGoogle Scholar
  24. Sacher AG, Le LW, Lau A, Earle CC, Leighl N (2015) Real-world chemotherapy treatment patterns in metastatic non–small cell lung cancer: are patients undertreated? Cancer 121(15):2562–2569CrossRefPubMedGoogle Scholar
  25. Stewart DJ (2007) Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 63(1):12–31CrossRefPubMedGoogle Scholar
  26. Stewart B, Wild CP (2014) World Cancer Report 2014: World Health Organization, GenevaGoogle Scholar
  27. Sweetman S (2017) Martindale: the complete drug reference. Pharmaceutical Press, LondonGoogle Scholar
  28. Vijayvergia N, Li T, Wong Y-N, Hall MJ, Cohen SJ, Dotan E (2016) Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer: chemotherapy adoption in older patients with CRC. Cancer 122(20):3191–3198CrossRefPubMedPubMedCentralGoogle Scholar
  29. Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4(4):307–320CrossRefPubMedGoogle Scholar
  30. Wheate NJ, Walker S, Craig GE, Oun R (2010) The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 39(35):8113–8127CrossRefPubMedGoogle Scholar
  31. Yanagimoto Y, Takiguchi S, Miyazaki Y, Makino T, Takahashi T, Kurokawa Y, Yamasaki M, Miyata H, Nakajima K, Hosoda H, Kangawa K, Mori M, Doki Y (2016) Improvement of cisplatin-related renal dysfunction by synthetic ghrelin: a prospective randomised phase II trial. Brit J Cancer 114:1318–1325CrossRefPubMedGoogle Scholar
  32. Yang CH, Fukuoka M, Mok TS, Wu YL, Thongprasert S, Saijo N, Chu DT, Jiang H, Duffield EL, Ichinose Y (2010) Final overall survival (OS) results from a Phase III, randomised, open-label, first-line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small cell lung cancer (NSCLC) in Asia. Ann Oncol 21:1–2CrossRefGoogle Scholar
  33. Zalba S, Garrido MJ (2013) Liposomes, a promising strategy for the clinical application of platinum derivatives. Expert Opin Drug Deliv 10(6):829–844CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Sydney Pharmacy SchoolThe University of SydneySydneyAustralia
  2. 2.Charles Perkins CentreThe University of SydneySydneyAustralia
  3. 3.Centre for Education and Research in AgeingConcord Repatriation General HospitalSydneyAustralia
  4. 4.Oncology Pharmacy DepartmentConcord Repatriation General HospitalSydneyAustralia
  5. 5.Concord Cancer Centre, Concord Repatriation General Hospital and Sydney Medical SchoolThe University of SydneySydneyAustralia

Personalised recommendations